Online citations, reference lists, and bibliographies.

HMG-CoA Reductase Inhibitors

Bruinvels Infarm Sweelincklaan
Published 2002 ·

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1136/bmj.312.7038.1061
C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study
M. Mendall (1996)
10.1161/01.RES.87.10.840
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.
H. Cai (2000)
Atherosclerotic plaque rupture and thrombosis. Evolving concepts.
V. Fuster (1990)
10.1016/0002-9149(94)90322-0
Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels.
J. Isaacsohn (1994)
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
O. Ozdemir (2000)
10.2741/a621
Transcriptional regulation of the human apolipoprotein genes.
V. Zannis (2001)
10.1074/jbc.270.37.21958
Molecular Cloning and Functional Analysis of the Promoter of the Human Squalene Synthase Gene (*)
G. Guan (1995)
10.1128/MCB.20.2.429-440.2000
Helix-Loop-Helix Proteins: Regulators of Transcription in Eucaryotic Organisms
M. Massari (2000)
10.1056/NEJM199901143400207
Atherosclerosis is an inflammatory disease.
R. Ross (1999)
10.11501/3075846
Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes
田中 誠 (1994)
Sterol regulation of acetyl coenzyme A carboxylase promoter requires two interdependent binding sites for sterol regulatory element binding proteins.
M. M. Magaña (1997)
10.1016/S0378-1119(99)00559-4
Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2.
A. Fra (2000)
10.1073/PNAS.95.15.8880
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
M. Endres (1998)
10.1073/pnas.93.3.1049
Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid.
J. M. López (1996)
10.1091/MBC.10.7.2221
Nuclear import of sterol regulatory element-binding protein-2, a basic helix-loop-helix-leucine zipper (bHLH-Zip)-containing transcription factor, occurs through the direct interaction of importin beta with HLH-Zip.
Emi Nagoshi (1999)
10.1001/jama.1996.03540130037027
Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study.
J. Ware (1996)
10.1016/0092-8674(85)90078-9
Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme
G. Gil (1985)
10.1016/0002-9149(91)90378-X
Pathogenesis of thrombosis in unstable angina.
J. Chesebro (1991)
10.1016/S0140-6736(05)70492-X
Thrombotic thrombocytopenic purpura and simvastatin
L. Mccarthy (1998)
Kwiterovich PO (1996) Small, dense low-density lipoprotein particles and coronary
J Coresh (1996)
ABCG5/8 genes responsible for serum plant sterol increase during stativ treatment
TA Miettinen (2001)
Monitoring the progress of the 2010 target for coronary heart disease mortality: estimated consequences on CHD incidence and mortality from changing prevalence of risk factors: a report for the Chief Medical Officer
K. Mcpherson (2001)
Kjekshus J, for the Scandinavian Simvastatin Study Group (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
TA Miettinen (1997)
10.1161/01.ATV.15.2.247
Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia
A. Notarbartolo (1995)
10.1016/S0735-1097(99)00525-2
The evolving role of statins in the management of atherosclerosis.
C. Vaughan (2000)
Triglyceride-rich proteins isolated by selected affinity
ST Kunitake (1994)
10.1016/0005-2760(91)90171-D
Effect of simvastatin on the synthesis and secretion of lipoproteins in relation to the metabolism of cholesterol in cultured hepatocytes.
A. Ribeiro (1991)
10.1074/jbc.271.51.32689
Two Tandem Binding Sites for Sterol Regulatory Element Binding Proteins Are Required for Sterol Regulation of Fatty-acid Synthase Promoter*
M. M. Magaña (1996)
10.1067/MHJ.2001.115297
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
M. Albert (2001)
10.1016/S0002-9149(97)00174-4
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
M. Davidson (1997)
10.1074/jbc.270.44.26292
DNA Binding Specificities and Pairing Rules of the Ah Receptor, ARNT, and SIM Proteins (*)
H. Swanson (1995)
10.1073/PNAS.95.13.7643
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products.
X. Wang (1998)
10.1172/JCI2265
Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.
J. Borén (1998)
10.1172/JCI10852
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
G. Martin (2001)
10.1074/jbc.273.26.16112
HLH106, a Drosophila Sterol Regulatory Element-binding Protein in a Natural Cholesterol Auxotroph*
J. Rosenfeld (1998)
10.1161/01.CIR.101.5.477
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
A. Gotto (2000)
10.1002/cyto.990220205
Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
I. Schmid (1995)
10.1161/01.CIR.98.9.839
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
P. Ridker (1998)
10.1128/MCB.17.9.5193
Promoter selective transcriptional synergy mediated by sterol regulatory element binding protein and Sp1: a critical role for the Btd domain of Sp1.
J. Athanikar (1997)
10.1016/S1097-2765(00)80006-4
Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs.
R. Rawson (1997)
10.1023/A:1007284217886
Differential expression of cytosolic and mitochondrial 3-hydroxy-3-methylglutaryl CoA synthases during adipocyte differentiation
J. M. López (2004)
Effects of the 3-hydroxy-3-methylglutary1-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-I and endothelial nitric oxide synthase in vascular endothelial cells
D Perez-Sala (1998)
10.1056/NEJM200003233421202
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
P. Ridker (2000)
Peripheral Blood Mononuclear Phagocyte Subpopulations as Cellular Markers in Hypercholesterolemia
GregorRothe (1996)
10.1056/NEJM199907083410202
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
B. Pitt (1999)
10.1161/01.CIR.90.2.775
Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture
P. Moreno (1994)
10.1038/43448
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
I. Shimomura (1999)
10.1161/01.ATV.19.7.1812
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
J. Alfón (1999)
10.1016/0026-0495(92)90050-K
Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man.
H. Vanhanen (1992)
10.1038/376037a0
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
D. Nicholson (1995)
10.1007/s005350070063
Protein-losing enteropathy associated with hypocomplementemia and anti-nuclear antibodies
A. Nakajima (2000)
10.1016/S0735-1097(86)80293-5
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
P. Canner (1986)
10.1016/S0002-9149(98)00423-8
Current and future treatment of hyperlipidemia: the role of statins.
M. Farnier (1998)
10.1074/jbc.274.32.22795
Autocatalytic Processing of Site-1 Protease Removes Propeptide and Permits Cleavage of Sterol Regulatory Element-binding Proteins*
P. Espenshade (1999)
10.1056/NEJM199811053391902
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
A. Tonkin (1998)
10.1182/blood.v82.10.3170.3170
The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients.
G. Fingerle (1993)
10.1126/science.272.5258.50
The Instructive Role of Innate Immunity in the Acquired Immune Response
D. Fearon (1996)
Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Lisa J. Wilcox (1999)
10.1016/0955-0674(94)90055-8
Cdk inhibitors: on the threshold of checkpoints and development.
S. Elledge (1994)
10.1016/S0955-0674(96)80084-6
Adipocyte differentiation: a transcriptional regulatory cascade.
R. Brun (1996)
10.1038/366701a0
p21 is a universal inhibitor of cyclin kinases
Y. Xiong (1993)
10.1177/00912709922007886
The Effects of Fluvastatin, a CYP2C9 Inhibitor, on Losartan Pharmacokinetics in Healthy Volunteers
A. M. Meadowcroft (1999)
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
H. Kempen (1988)
10.1161/01.ATV.17.8.1521
Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.
M. Kimura (1997)
10.1016/S0049-3848(01)00255-9
Alternative binding assay of GP IIb/IIIa antagonists with a nonradioactive labeling method of platelets.
J. Alfón (2001)
10.1074/jbc.M001066200
The Roles of Sterol Regulatory Element-binding Proteins in the Transactivation of the Rat ATP Citrate-Lyase Promoter*
Y. Moon (2000)
10.1055/s-2007-994014
Hypercholesterolemia and platelets.
E. Tremoli (1993)
10.1073/pnas.111138698
Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR
J. Ou (2001)
10.1247/csf.20.421
Regulation of intracellular cholesterol metabolism.
R. Sato (1995)
10.1016/0888-7543(95)80009-B
Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13.
X. Hua (1995)
10.1161/01.CIR.95.5.1126
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
G. O’Driscoll (1997)
10.1074/jbc.272.15.10295
Multiple Sequence Elements are Involved in the Transcriptional Regulation of the Human Squalene Synthase Gene*
G. Guan (1997)
10.1016/S0735-1097(98)00522-1
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
M. Pfeffer (1999)
10.1016/0167-5699(94)90137-6
The acute phase response.
H. Baumann (1994)
10.1097/00041433-200104000-00004
Xol INXS: role of the liver X and the farnesol X receptors
E. Fayard (2001)
Effect of glucose on sterol regulatory element binding protein (SREBP)-I in pancreatic beta cells
M Laudes (2001)
Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies for coronary prevention. Atherosclerosis
D Wood (1998)
10.1016/S1062-1458(01)00460-3
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
P. Ridker (2001)
10.1016/S0140-6736(89)90953-7
INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES
P. Richardson (1989)
10.1074/jbc.272.50.31725
Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Blocks Hypoxia-mediated Down-regulation of Endothelial Nitric Oxide Synthase*
U. Laufs (1997)
10.1016/S0092-8674(00)81304-5
Sterol-Regulated Release of SREBP-2 from Cell Membranes Requires Two Sequential Cleavages, One Within a Transmembrane Segment
J. Sakai (1996)
10.1182/blood.V85.10.2910.bloodjournal85102910
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.
M. Saleh (1995)
10.1056/NEJM199502233320802
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
T. Anderson (1995)
10.1126/SCIENCE.286.5446.1946
Stimulation of bone formation in vitro and in rodents by statins.
G. Mundy (1999)
10.1007/s002280050562
Statins and peripheral neuropathy
U. Jeppesen (1999)
10.1161/01.ATV.17.2.265
Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
S. Colli (1997)
10.1161/01.ATV.19.10.2348
Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation.
S. Bhakdi (1999)
10.1007/BF00278470
Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia
H. Vanhanen (1992)
10.2337/diacare.20.4.614
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
K. Pyoeraelae (1997)
10.1101/GAD.14.11.1293
Transcriptional regulation of adipogenesis.
E. Rosen (2000)
10.1161/01.ATV.18.9.1424
Enhanced upregulation of the Fc gamma receptor IIIa (CD16a) during in vitro differentiation of ApoE4/4 monocytes.
J. Stöhr (1998)
10.1136/bmj.315.7122.1577
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin
J. Caro (1997)
10.1161/01.ATV.20.1.189
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
M. Guerin (2000)
10.1016/S0167-5273(97)00238-6
Molecular biology of atherosclerosis.
P. Libby (1997)
10.1038/362801a0
The pathogenesis of atherosclerosis: a perspective for the 1990s
R. Ross (1993)
10.1161/01.CIR.93.10.1796
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
T. Pedersen (1996)
10.7326/0003-4819-132-10-200005160-00003
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
D. Ganz (2000)
10.1136/bmj.303.6797.276
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
Z. Chen (1991)
10.1046/J.1365-3083.1999.00559.X
Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice.
X. Zhou (1999)
10.1074/jbc.273.40.26138
Differential Stimulation of Cholesterol and Unsaturated Fatty Acid Biosynthesis in Cells Expressing Individual Nuclear Sterol Regulatory Element-binding Proteins*
J. T. Pai (1998)
10.1161/01.CIR.97.12.1129
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
U. Laufs (1998)
10.1182/blood.V74.7.2527.bloodjournal7472527
Identification and characterization of a novel monocyte subpopulation in human peripheral blood.
B. Passlick (1989)
10.1161/01.ATV.15.9.1359
Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
M. Guerin (1995)
10.1073/PNAS.94.23.12354
Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver.
I. Shimomura (1997)
10.1038/82219
Statins as a newly recognized type of immunomodulator
B. Kwak (2000)
10.1161/01.ATV.15.10.1652
Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia.
T. Gauthier (1995)
10.1016/0092-8674(87)90713-6
42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter
T. Südhof (1987)
Platelet Cytosolic Ca2+ and Membrane Dynamics in Patients With Primary Hypercholesterolemia
Kim-Hanh Le QuanSang (1995)
10.1016/S0008-6363(00)00247-9
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
A. Lefer (2001)
10.1016/0735-1097(94)90657-2
Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.
A. Fernández-Ortíz (1994)
10.1056/NEJM199506293322607
The primary prevention of coronary heart disease in women.
J. Rich-Edwards (1995)
10.1006/PMED.1999.0513
Primordial prevention of cardiovascular disease through applied genetics.
R. Williams (1999)
Lipotoxicity of-Cells in Obesity and in Other Causes of Fatty Acid Spillover
R. Unger (2001)
10.1161/01.RES.88.3.268
LDL Downregulates CYP51 in Porcine Vascular Endothelial Cells and in the Arterial Wall Through a Sterol Regulatory Element Binding Protein-2–Dependent Mechanism
C. Rodríguez (2001)
10.1097/00041433-199708000-00004
Peroxisome proliferator-activated receptor gamma and the control of adipogenesis.
R. Brun (1997)
10.1097/00075197-200007000-00006
Nutritional and insulin regulation of leptin gene expression.
N. Iritani (2000)
Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching.
J. Frank (1989)
10.1074/jbc.271.21.12247
A Direct Role for Sterol Regulatory Element Binding Protein in Activation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Gene (*)
S. Vallett (1996)
10.1016/S0192-0561(96)00068-9
Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line.
S. Niwa (1996)
10.1074/jbc.273.20.12526
Differential Transcriptional Regulation of the Human Squalene Synthase Gene by Sterol Regulatory Element-binding Proteins (SREBP) 1a and 2 and Involvement of 5′ DNA Sequence Elements in the Regulation*
G. Guan (1998)
10.1016/S0163-7258(99)00045-5
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
A. Corsini (1999)
10.1101/gad.10.9.1096
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.
J. Kim (1996)
10.1016/0021-9150(93)90172-Q
Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
F. Bernini (1993)
10.1073/pnas.93.24.13709
Recurrent G-to-A substitution in a single codon of SREBP cleavage-activating protein causes sterol resistance in three mutant Chinese hamster ovary cell lines.
A. Nohturfft (1996)
10.1128/MCB.15.5.2582
Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain.
J. Kim (1995)
10.1016/S0733-8651(05)70073-4
Histopathology of plaque rupture.
H. Ravn (1999)
10.1073/pnas.94.10.5172
A natural classification of the basic helix-loop-helix class of transcription factors.
W. Atchley (1997)
10.1073/pnas.92.4.935
Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver.
Z. Sheng (1995)
10.1161/01.CIR.97.24.2433
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.
M. Aikawa (1998)
10.1074/jbc.270.3.1161
Cooperation by Sterol Regulatory Element-binding Protein and Sp1 in Sterol Regulation of Low Density Lipoprotein Receptor Gene (*)
H. Sanchez (1995)
Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver.
I. Björkhem (1987)
10.1016/S0735-1097(99)00018-2
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
G. Dangas (1999)
10.1006/BBRC.1997.8030
Molecular cloning of the promoter for rat hepatic neutral cholesterol ester hydrolase: evidence for transcriptional regulation by sterols.
R. Natarajan (1998)
10.1006/geno.1996.4525
Structure of the human gene encoding sterol regulatory element binding protein 2 (SREBF2).
A. Miserez (1997)
10.1161/01.CIR.99.6.779
Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study
M. Lorgeril (1999)
10.1016/S0049-3848(99)00037-7
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.
G. Huhle (1999)
10.1001/ARCHINTE.159.22.2661
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
S. Haffner (1999)
10.2165/00003495-199856001-00002
New Insights into Plaque Stabilisation by Lipid Lowering
P. Libby (2012)
10.1016/S0092-8674(00)81362-8
Sterol Resistance in CHO Cells Traced to Point Mutation in SREBP Cleavage–Activating Protein
X. Hua (1996)
10.1055/s-0038-1642727
Thrombin functions and antithrombotic intervention.
J. Fenton (1995)
10.1073/pnas.87.12.4722
Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains.
A. Voronova (1990)
10.1161/01.CIR.102.25.3104
Suppression of Endothelial Nitric Oxide Production After Withdrawal of Statin Treatment Is Mediated by Negative Feedback Regulation of Rho GTPase Gene Transcription
U. Laufs (2000)
Multiple sterol regulatory elements in promoter for hamster 3-hydroxy-3-methylglutaryl-coenzyme A synthase.
J. Smith (1988)
ADD-1/SREBP-1 is a major determinant of tissue differential lipogenic capacity in mammalian and avian species.
F. Gondret (2001)
10.1006/GENO.2001.6546
Analysis of mouse retinal dehydrogenase type 2 promoter and expression.
X. Wang (2001)
10.1056/NEJM199302043280504
Serum cholesterol in young men and subsequent cardiovascular disease.
M. Klag (1993)
10.1084/jem.182.6.1959
On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety
S. Bhakdi (1995)
10.1073/pnas.93.2.945
Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene.
J. Ericsson (1996)
10.1073/PNAS.95.9.4935
Specificity in cholesterol regulation of gene expression by coevolution of sterol regulatory DNA element and its binding protein.
J. Athanikar (1998)
10.1074/jbc.274.20.14508
YY1 Is a Negative Regulator of Transcription of Three Sterol Regulatory Element-binding Protein-responsive Genes*
J. Ericsson (1999)
10.1016/S0002-9149(97)00532-8
Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
J. Zambrana (1997)
10.1161/01.RES.83.7.683
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.
M. Essig (1998)
Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes.
V. Bazil (1991)
Cell cycle progression and cell growth in mammalian cells
A Zetterberg (1995)
Dietary stano I ester in statin-treated coronary patients with high basal cholesterol
H Gylling (1998)
10.1161/01.STR.24.4.614.a
Secular trends in stroke incidence and mortality.
J. Grotta (1993)
10.1016/S0092-8674(00)80213-5
The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor
M. Brown (1997)
10.1074/jbc.274.40.28549
Failure to Cleave Sterol Regulatory Element-binding Proteins (SREBPs) Causes Cholesterol Auxotrophy in Chinese Hamster Ovary Cells with Genetic Absence of SREBP Cleavage-activating Protein*
R. Rawson (1999)
10.1161/01.ATV.20.2.556
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.
T. Bourcier (2000)
10.1038/79510
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.
Yasuko Kureishi (2000)
10.1001/archinte.1993.00410090025004
Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data.
R. Kronmal (1993)
10.1016/S0140-6736(96)90217-2
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?
Z. Massy (1996)
10.1016/S0002-9149(96)00684-4
Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
M. Bevilacqua (1997)
10.1016/0092-8674(87)90015-8
A new class of yeast transcriptional activators
J. Ma (1987)
10.1161/01.CIR.92.7.1758
Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
R. Salonen (1995)
10.1038/KI.1997.423
Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway.
F. Vrtovsnik (1997)
10.1016/S0021-9150(00)00417-2
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
M. T. Montero (2000)
10.1253/JCJ.61.965
Perforin-secreting killer cell infiltration in the aortic tissue of patients with atherosclerotic aortic aneurysm.
Y. Seko (1997)
10.1111/j.1365-2796.1990.tb00124.x
Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.
G. Vega (1990)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPSrrexCAPS
C. Berry (1998)
10.1016/S0002-9149(00)00910-3
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.
T. Pedersen (2000)
LPS and ceramide docking to CDI4 provokes differential raft domain clustering
A Pfeiffer (2001)
SREBP-I mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I
R Streicher (1996)
10.1056/NEJM200012213432513
Pravastatin therapy and the risk of stroke.
Brett As (2000)
10.1161/01.CIR.98.8.731
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
P. Ridker (1998)
10.1016/S0009-9236(98)90067-4
The interaction of diltiazem with lovastatin and pravastatin
N. Azie (1998)
10.1111/j.1476-5381.1992.tb14517.x
S‐nitroso‐glutathione inhibits platelet activation in vitro and in vivo
M. Radomski (1992)
10.1038/40187
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
M. Uehata (1997)
10.1016/S0002-9149(97)00695-4
Effects of lovastatin on the immune system.
M. Muldoon (1997)
10.1161/01.ATV.18.10.1643
Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys.
L. Hale (1998)
10.2337/DIABETES.48.5.1113
Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.
Stephan Jacob (1999)
10.1128/MCB.21.9.2991-3000.2001
Identification of Liver X Receptor-Retinoid X Receptor as an Activator of the Sterol Regulatory Element-Binding Protein 1c Gene Promoter
T. Yoshikawa (2001)
10.1074/jbc.273.34.22052
Transcriptional Activation of the Stearoyl-CoA Desaturase 2 Gene by Sterol Regulatory Element-binding Protein/Adipocyte Determination and Differentiation Factor 1*
D. Tabor (1998)
Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence.
M. R. Briggs (1993)
10.1016/0021-9150(89)90017-8
Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.
C. Malmendier (1989)
10.1016/0092-8674(94)90006-X
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
P. Tontonoz (1994)
Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.
P. Shah (1995)
10.1055/s-0038-1642665
Thrombin specificity.
M. C. Guillin (1995)
Molecular bases of the acute coronary syndromes
P Libby (1995)
10.1161/01.CIR.99.2.237
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
W. Koenig (1999)
10.1056/NEJM197402212900805
Platelet function in hyperlipoproteinemia.
A. Carvalho (1974)
10.1111/j.1532-5415.1988.tb04370.x
Proportional Hazards Analysis of Risk Factors for Coronary Heart Disease in Individuals Aged 65 or Older
T. Harris (1988)
Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: functional role of the transcription factors SREBP-1a, -2, and YY1.
B. Gauthier (1999)
10.1006/bbrc.1996.0265
Regulation of fatty acid synthase expression by cholesterol in human cultured cells.
Y. Kawabe (1996)
10.1161/01.RES.77.5.863
Matrix metalloproteinases and cardiovascular disease.
C. Dollery (1995)
10.1146/ANNUREV.NUTR.18.1.297
Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport.
C. Bruce (1998)
10.1038/ki.1988.125
Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
G. Vega (1988)
10.1007/S11883-000-0027-Y
Pathophysiology of atherosclerosis: Development, regression, restenosis
M. Adams (2000)
10.1172/JCI119247
Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells.
I. Shimomura (1997)
10.1161/01.CIR.103.2.276
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro
M. Aikawa (2001)
10.1161/01.ATV.18.5.783
Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
A. Mohammadi (1998)
10.1073/PNAS.95.11.5987
Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice.
J. Horton (1998)
10.1161/01.ATV.20.5.1177
Natural history and histological classification of atherosclerotic lesions: an update.
H. Stary (2000)
10.1159/000174688
Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
A. Alberts (1990)
10.1073/pnas.93.3.1195
HLH106, a Drosophila transcription factor with similarity to the vertebrate sterol responsive element binding protein.
U. Theopold (1996)
10.1016/S0955-0674(99)00076-9
Cholesterol in signal transduction.
J. Incardona (2000)
Coronary Prevention Study (WOSCOPS). Circulation
BG Brown (1993)
10.1007/978-94-009-0311-1_54
Noncholesterol Serum Sterols in Scandinavian Simvastatin Survival Study
Tatu Miettinen (1996)
10.1161/01.ATV.13.2.170
Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
A. Gaw (1993)
Role for sterol regulatory element binding protein in the regulation of farnesyl diphosphate synthase and in the control of cellular levels of cholesterol and triglyceride: evidence from sterol regulation-defective cells.
S. Jackson (1996)
10.1097/00041433-199710000-00008
Scavenging, signalling and adhesion coupling in macrophages: implications for atherogenesis
G. Schmitz (1997)
10.1101/gad.8.16.1910
Sterol-resistant transcription in CHO cells caused by gene rearrangement that truncates SREBP-2.
J. Yang (1994)
10.1016/0002-9149(88)90002-1
Discovery, biochemistry and biology of lovastatin.
A. Alberts (1988)
10.1038/19789
Composite co-activator ARC mediates chromatin-directed transcriptional activation
A. Näär (1999)
10.1055/S-2007-995828
Thrombin and antithrombotics.
J. Fenton (1998)
10.1161/01.ATV.18.11.1671
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.
S. Bellosta (1998)
Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol.
S. Colles (1996)
10.1016/S0140-6736(05)70491-8
Atorvastatin-induced severe thrombocytopenia
M. L. González-Ponte (1998)
10.7326/0003-4819-74-1-1
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
W. Kannel (1971)
10.1161/01.HYP.37.6.1450
HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
S. Wassmann (2001)
10.1074/jbc.273.35.22409
Sterol Regulatory Element Binding Protein-1 Activates the Cholesteryl Ester Transfer Protein Gene in Vivobut Is Not Required for Sterol Up-regulation of Gene Expression*
R. A. Chouinard (1998)
Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Y. Arad (1990)
10.1074/jbc.273.37.24266
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase*
U. Laufs (1998)
10.1007/S11883-000-0067-3
Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms
J. Plutzky (2000)
10.1345/aph.10211
Do HMG-CoA Reductase Inhibitors Affect Fibrinogen?
J. Song (2001)
Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization.
X. Wang (1993)
Effects of bile acid feeding and depletion on plasma and biliary squalene, methyl sterols and lathosterol.ln: G Paumgartner, A Stiehl, W Gerok (eds): Bile Acids and Lipids
TA Miettinen (1981)
10.1007/978-3-0348-8239-2_1
Atherosclerosis: an inflammatory disease
G. Schmitz (2001)
10.1097/00041433-200106000-00002
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice
I. P. Torra (2001)
10.1016/S0002-9149(97)00904-1
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
T. Pedersen (1998)
10.1056/NEJM199807233390404
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
S. Haffner (1998)
10.1016/J.ATHEROSCLEROSISSUP.2004.08.027
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
T. Pedersen (2004)
Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
L. Weiner (1994)
10.1097/00041433-199810000-00012
The response-to-retention hypothesis of atherogenesis reinforced.
K. Williams (1998)
10.1016/S0021-9150(99)00061-1
A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease.
G. Rothe (1999)
10.1016/S0002-9149(98)00136-2
Direct medical costs of coronary artery disease in the United States.
M. W. Russell (1998)
10.1093/NAR/27.4.1104
DNA binding specificity and transactivation properties of SREBP-2 bound to multiple sites on the human apoA-II promoter.
H. Kan (1999)
10.1002/ajh.2830440208
Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
H. Wada (1993)
C-reactive protein: binding to lipids and lipoproteins.
M. Pepys (1985)
10.1172/JCI113259
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.
H. Ginsberg (1987)
10.1056/NEJM198904063201407
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
D. Steinberg (1989)
10.1016/S0735-1097(98)00487-2
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
C. Bustos (1998)
10.1182/blood.v93.4.1308
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
J. Dimitroulakos (1999)
10.1101/GAD.12.20.3182
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy.
I. Shimomura (1998)
10.1016/S0021-9150(00)00757-7
Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia.
C. Serrano (2001)
10.1016/S0002-9149(99)00183-6
Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
W. Maerz (1999)
10.1679/aohc.58.307
Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in athero-resistant and athero-prone areas of the normal aorta.
Y. Bobryshev (1995)
10.1046/J.1365-2796.2000.00681.X
Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study.
T. Hillen (2000)
10.1016/S0735-1097(98)81868-8
Basal non-cholesterol sterols reveal a subgroup of 4S not benefitted by simvastatin-induced decrease of recurrent coronary events
T. Miettinen (1998)
Simvastatin reduces
D Ferro (1997)
10.1056/NEJM199610033351401
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F. Sacks (1996)
Effects of atorvastatin on early recurrent ischemic events in acute coro
S Leslie (2001)
Primary prevention of acute coronary events with lovastatin in men
W Kruyer (1998)
10.1016/S0046-8177(87)80168-5
An immunohistochemical analysis of human aortic fatty streaks.
J. Munro (1987)
10.1074/jbc.273.28.17865
CBP Is Required for Sterol-regulated and Sterol Regulatory Element-binding Protein-regulated Transcription*
J. Ericsson (1998)
10.1021/BI991721H
p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism.
A. Bist (2000)
10.1161/01.CIR.100.11.1215
Dietary lipid lowering reduces tissue factor expression in rabbit atheroma.
M. Aikawa (1999)
10.1172/JCI9639
Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
U. Laufs (2000)
Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
A. D. Marais (1997)
10.1016/0006-291X(89)92773-3
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
J. Germershausen (1989)
10.1073/pnas.92.9.3893
T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.
S. Stemme (1995)
10.1172/JCI5754
The IL-1 receptor and Rho directly associate to drive cell activation in inflammation.
R. Singh (1999)
10.1093/OXFORDJOURNALS.JBCHEM.A022060
Multiple DNA elements for sterol regulatory element-binding protein and NF-Y are responsible for sterol-regulated transcription of the genes for human 3-hydroxy-3-methylglutaryl coenzyme A synthase and squalene synthase.
J. Inoue (1998)
10.1016/s0889-8588(18)30201-6
Understanding thrombin and hemostasis.
J. Fenton (1993)
10.1038/sj.bjp.0704070
A new HMG‐CoA reductase inhibitor, rosuvastatin, exerts anti‐inflammatory effects on the microvascular endothelium: the role of mevalonic acid
T. Stalker (2001)
10.1016/0092-8674(89)90682-X
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins
C. Murre (1989)
10.1016/0021-9150(94)05474-W
Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.
H. Vanhanen (1995)
10.1097/00007890-199806150-00003
Prevention of primary islet isograft nonfunction in mice with pravastatin.
S. Arita (1998)
10.1007/s003359900363
Hormone-sensitive lipase (Lipe): Sequence analysis of the 129Sv mouse Lipe gene
R. Sztrolovics (2009)
10.1161/01.ATV.19.3.519
Atherosclerotic aortic gangliosides enhance integrin-mediated platelet adhesion to collagen.
F. Wen (1999)
10.1016/S0002-9149(00)01339-4
Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization.
P. Libby (2000)
10.1016/S0735-1097(97)00424-5
Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging.
S. Meisel (1998)
10.1172/JCI115196
Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta.
J. Allen (1991)
Oxidized LDL
K Brand (1994)
Simvastatin Survival Study (4S) group
K Pyorala (1997)
SREBP-I , a basic-helix-Ioop-helix-Ieucine zipper protein that controls transcription of the low density lipoprotein receptor
C Yokoyama (1993)
10.1161/01.ATV.20.2.500
Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation.
A. Vuorio (2000)
10.1002/j.1460-2075.1996.tb00438.x
Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis.
X. Wang (1996)
10.1056/NEJM198911093211913
Serum cholesterol levels and stroke mortality.
Z. Chen (1989)
10.1006/JMBI.2000.4218
Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and is independent of the presence of multiple E boxes.
K. Schoonjans (2000)
10.1074/jbc.273.32.19938
Identification of Diazepam-binding Inhibitor/Acyl-CoA-binding Protein as a Sterol Regulatory Element-binding Protein-responsive Gene*
J. Swinnen (1998)
10.1007/BF01606532
Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis
H. Kishikawa (2005)
10.1161/01.cir.97.15.1440
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
C. Packard (1998)
10.1111/J.1749-6632.2000.TB06300.X
The role of adaptive immunity in atherosclerosis.
G. Hansson (2000)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
J. Shepherd (1995)
10.1161/01.ATV.18.7.1093
Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and VCAM-1.
R. Scalia (1998)
10.1016/J.ATHEROSCLEROSISSUP.2004.08.021
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.
A. Endo (1976)
10.1093/oxfordjournals.aje.a115479
Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.
T. Miettinen (1990)
10.1164/AJRCCM.157.5.9709020
Lovastatin induces apoptosis in malignant mesothelioma cells.
J. Rubins (1998)
10.1093/oxfordjournals.eurheartj.a015225
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
K. Mitropoulos (1997)
10.1001/archinte.1997.00440330039004
Reductase inhibitor monotherapy and stroke prevention.
J. Crouse (1997)
10.1073/pnas.76.1.333
Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.
J. Goldstein (1979)
CoA reductase was mevastatin (compactin, ML-236B), which was isolated from Penicillium citrinium
A. Endo (1976)
10.1016/S0008-6363(00)00146-2
Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
K. Koh (2000)
10.1210/en.140.12.5669
Sterol regulatory element-binding protein-1a binds to cis elements in the promoter of the rat high density lipoprotein receptor SR-BI gene.
D. Lopez (1999)
10.1056/NEJM199912093412415
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
D. Cohen (1999)
10.1074/jbc.M101661200
Cholesterol Biosynthesis from Lanosterol
J. Kim (2001)
10.1056/NEJM199502233320807
Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.
G. Levine (1995)
10.1111/j.1365-2249.1994.tb05499.x
Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV‐infected patients
W. A. Nockher (1994)
10.1177/0272989X9301300409
Markov Models in Medical Decision Making
F. Sonnenberg (1993)
10.1016/S0092-8674(00)00037-4
Regulated Step in Cholesterol Feedback Localized to Budding of SCAP from ER Membranes
A. Nohturfft (2000)
10.1161/01.ATV.20.5.1340
Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol.
T. Miettinen (2000)
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
S. Grundy (1985)
10.1096/fj.00-0590
Diseases of liporegulation: new perspective on obesity and related disorders
R. Unger (2001)
10.1097/00004872-198608000-00019
STOP-hypertension: Swedish trial in old patients with hypertension.
B. Dahlöf (1986)
10.1111/j.1432-1033.1978.tb12380.x
Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.
I. Kaneko (1978)
10.1016/S0021-9150(00)00468-8
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Y. Rikitake (2001)
10.1161/01.CIR.96.12.4226
Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol.
H. Gylling (1997)
10.1161/01.cir.100.2.178
Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.
A. Lefer (1999)
10.1074/jbc.270.49.29422
Hairpin Orientation of Sterol Regulatory Element-binding Protein-2 in Cell Membranes as Determined by Protease Protection *
X. Hua (1995)
10.1056/NEJM199502233320801
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
C. B. Treasure (1995)
10.1016/S0735-1097(00)00924-4
HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.
Z. Yang (2000)
10.1101/GAD.12.19.3020
Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro.
A. Näär (1998)
10.1073/pnas.86.8.2713
Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation.
A. Suits (1989)
10.1074/jbc.272.11.7298
Identification of Glycerol-3-phosphate Acyltransferase as an Adipocyte Determination and Differentiation Factor 1- and Sterol Regulatory Element-binding Protein-responsive Gene*
J. Ericsson (1997)
Kjekshus J for the Scandinavian Simvastatin Study Group (1997) Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
TA Miettinen (1997)
tors for myocardial infarction in a cohort of 5790 men. Atherosclerosis
F Oram (1996)
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-l and endothelial nitric oxide synthase in vascular endothelial cells
D Perez-Sala (1998)
and differentiation . factor associated with adipocyte determination ADD 1 : a novel helix-loop-helix transcription
P. Tontonoz (1993)
10.1002/jcp.1041390314
Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
J. Cutts (1989)
10.1073/pnas.92.13.6102
Domains of transcription factor Sp1 required for synergistic activation with sterol regulatory element binding protein 1 of low density lipoprotein receptor promoter.
L. Yieh (1995)
Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation.
D. Baldassarre (1997)
10.1016/S0735-1097(97)00324-0
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
C. Weber (1997)
10.1161/01.CIR.85.5.1792
Increased Thromboxane Biosynthesis in Type IIa Hypercholesterolemia
G. Daví (1992)
10.1172/JCI111618
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
D. D. Illingworth (1984)
10.1136/hrt.69.5.377
Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.
M. Davies (1993)
10.1084/JEM.190.4.585
The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II
D. Bharadwaj (1999)
10.7326/0003-4819-107-5-609
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.
R. Havel (1987)
Influence of cholesterol-lowering on plasma membrane lipids and function.
P. Lijnen (1996)
10.1126/science.3873704
Cassette of eight exons shared by genes for LDL receptor and EGF precursor.
T. Südhof (1985)
10.3109/07853890008998838
Associations between change in C-reactive protein and serum lipids during statin treatment
T. Strandberg (2000)
10.1161/01.CIR.95.4.1062
Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis.
D. Steinberg (1997)
Single nucleotide resolution of sterol regulatory region in promoter for 3-hydroxy-3-methylglutaryl coenzyme A reductase.
T. Osborne (1991)
10.1210/ENDO.142.1.7868
Yin yang 1 protein negatively regulates high-density lipoprotein receptor gene transcription by disrupting binding of sterol regulatory element binding protein to the sterol regulatory element.
W. Shea-Eaton (2001)
10.1074/JBC.273.27.17243
Topology of SREBP Cleavage-activating Protein, a Polytopic Membrane Protein with a Sterol-sensing Domain*
A. Nohturfft (1998)
10.1074/jbc.271.43.26461
Sterol-dependent Transcriptional Regulation of Sterol Regulatory Element-binding Protein-2*
R. Sato (1996)
Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia
BG Jakob (1992)
Pet al (1999) ADDI/SREBP-Ic is required in the activation of hepatic lipogenic gene expression by glucose
M Foretz (1999)
10.1016/s1062-1458(01)00376-2
Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia
P. Ridker (2001)
Cholesterol metabolism during hypolipidemic treatment with inhibitors of cholesterol synthesis
TA Miettinen (1990)
10.1038/381516a0
Role of the thrombin receptor in development and evidence for a second receptor
A. Connolly (1996)
10.1016/S0092-8674(00)80675-3
Regulated Intramembrane Proteolysis A Control Mechanism Conserved from Bacteria to Humans
M. Brown (2000)
10.3892/IJMM.3.1.63
Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition.
C. Mueller (1999)
10.1074/jbc.270.43.25578
Sterol Regulation of Fatty Acid Synthase Promoter
M. Bennett (1995)
10.1073/PNAS.94.20.10693
Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol.
A. Bist (1997)
10.1161/01.ATV.17.1.72
A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
C. Aguilar-Salinas (1997)
10.1016/S0167-5273(00)00439-3
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
J. Musial (2001)
10.1073/PNAS.97.15.8536
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.
T. Kakuma (2000)
10.7326/0003-4819-129-9-199811010-00002
Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial
S. Lewis (1998)
10.1136/hrt.82.3.325
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
D. M. Pickin (1999)
10.1126/science.271.5257.1861
Translational Control of p27Kip1 Accumulation During the Cell Cycle
L. Hengst (1996)
10.1016/S0021-9150(99)00011-8
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.
J. Frostegård (1999)
10.1172/JCI2961
Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.
J. Horton (1998)
10.1016/0021-9150(91)90116-K
Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products.
Joerg Kreuzer (1991)
10.1001/jama.1991.03460090093039
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
L. Goldman (1991)
10.1074/jbc.273.28.17801
Second-site Cleavage in Sterol Regulatory Element-binding Protein Occurs at Transmembrane Junction as Determined by Cysteine Panning*
E. A. Duncan (1998)
Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element.
T. Osborne (1988)
10.1210/ENDO.142.1.7867
Conditional response of the human steroidogenic acute regulatory protein gene promoter to sterol regulatory element binding protein-1a.
L. Christenson (2001)
Effects of changes in fat, fish, and References reinfarction trial
ML Burr (1989)
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
TR Pedersen (1998)
Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances; a case throwing new light on the action of insulin. (concluded).
R. Lawrence (1946)
10.1161/01.CIR.78.1.25
Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training.
P. Thompson (1988)
CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.
G. Wolbink (1996)
10.1139/o95-010
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.
E. Pau (1995)
10.1152/AJPCELL.2001.280.5.C1204
Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins.
P. Frank (2001)
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
C. Aguilar-Salinas (1995)
10.1055/S-2000-13209
Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions.
U. Landmesser (2000)
10.1097/00004647-199609000-00023
Enlarged Infarcts in Endothelial Nitric Oxide Synthase Knockout Mice are Attenuated by Nitro-L-Arginine
Z. Huang (1996)
10.1161/01.ATV.19.6.1456
SREBP-1 binds to multiple sites and transactivates the human ApoA-II promoter in vitro : SREBP-1 mutants defective in DNA binding or transcriptional activation repress ApoA-II promoter activity.
P. Pissios (1999)
10.1385/IR:21:2-3:167
Participation of innate and acquired immunity in atherosclerosis
L. Curtiss (2000)
10.1016/S0041-1345(98)01790-4
Statins inhibit T-cell interactions with elastin.
A. Górski (1999)
10.1101/GAD.11.18.2295
Rho GTPases and signaling networks.
L. Van Aelst (1997)
10.1056/NEJM199704033361401
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P. Ridker (1997)
10.1093/ajcn/43.1.92
Serum plant sterols and their relation to cholesterol absorption.
R. Tilvis (1986)
Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene.
T. Südhof (1987)
10.1016/S0735-1097(99)00019-4
The anti-thrombotic effects of statins.
D. Kearney (1999)
10.7326/0003-4819-132-10-200005160-00002
Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
L. Prosser (2000)
10.1073/PNAS.96.20.11041
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood.
M. Brown (1999)
10.1016/0002-8703(89)90237-8
Initial drug therapy for hypertensive patients with hyperlipidemia.
W. Kannel (1989)
10.1111/j.1365-2362.1995.tb01746.x
Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications
G. Watts (1995)
10.1016/S0940-2993(00)80107-4
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
P. Dansette (2000)
10.1017/CBO9780511586545.006
Morbidity, medication, and functional limitations in very old age
E. Steinhagen-Thiessen (1999)
Effect of statin therapy on C-reactive protein levels
M. Albert (2001)
10.1210/ENDO.142.4.8075
Sterol regulatory element binding protein-1a regulation of the steroidogenic acute regulatory protein gene.
W. Shea-Eaton (2001)
Elucidation of the role of plaque instability and rupture in acute coronary events
V Fuster (1995)
10.1093/OXFORDJOURNALS.MOLBEV.A026079
Evolution of bHLH transcription factors: modular evolution by domain shuffling?
Bernd Morgenstern (1999)
10.1016/S0021-9150(99)00105-7
Coronary C-reactive protein distribution: its relation to development of atherosclerosis.
Y. Zhang (1999)
10.7164/antibiotics.29.1346
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.
A. Endo (1976)
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase.
M. Tewari (1995)
10.1073/PNAS.96.22.12737
Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes.
M. Foretz (1999)
10.1161/01.CIR.97.15.1446
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
F. Sacks (1998)
10.1016/0021-9150(93)90024-O
Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.
C. Ahnadi (1993)
New and classical risk factors--the Münster heart study (PROCAM).
G. Assmann (1997)
10.1016/0021-9150(92)90039-J
Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations.
M. C. Burleigh (1992)
10.1161/01.CIR.95.1.76
Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.
O. Tamai (1997)
10.1073/pnas.89.2.599
Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins.
C. V. Dang (1992)
10.2105/AJPH.77.11.1417
Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.
M. Weinstein (1987)
Clinical-pathological correlations of coronary disease progression and regression.
V. Fuster (1992)
10.1074/jbc.273.3.1349
Sterol Regulation of 3-Hydroxy-3-Methylglutaryl-coenzyme A Synthase Gene through a Direct Interaction Between Sterol Regulatory Element Binding Protein and the Trimeric CCAAT-binding Factor/Nuclear Factor Y*
K. Dooley (1998)
10.1007/BF03258191
Inhibition of Dietary Cholesterol Absorption During Lovastatin (Mevinolin) Treatment
T. Miettinen (1990)
Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β
勝又 直樹 (2002)
10.1101/gad.10.22.2903
SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.
J. Oliner (1996)
10.1056/NEJM199801083380203
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
J. Kuivenhoven (1998)
10.1053/EUHJ.1998.1150
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
P. Serruys (1999)
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors.
A. Endo (1981)
10.1182/blood.V87.1.373.bloodjournal871373
Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis.
M. Frankenberger (1996)
10.1038/sj.onc.1203889
Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway
J. Swinnen (2000)
Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men.
H. Gylling (1996)
10.2165/00003495-199856001-00003
Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions
W. Mueck (2012)
10.1128/MCB.21.8.2779-2789.2001
Dimerization of Sterol Regulatory Element-Binding Protein 2 via the Helix-Loop-Helix-Leucine Zipper Domain Is a Prerequisite for Its Nuclear Localization Mediated by Importin β
Emi Nagoshi (2001)
10.1007/BF00185608
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia
K. Parhofer (1993)
10.1161/01.CIR.98.1.82
Cell cycle progression: new therapeutic target for vascular proliferative disease.
R. Braun-Dullaeus (1998)
10.1016/S0021-9150(99)00053-2
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
J. R. Schaefer (1999)
10.1097/00041433-199612000-00008
Statins: within-group comparisons, statin escape and combination therapy
M. Tikkanen (1996)
10.1136/bmj.304.6824.431
Should there be a moratorium on the use of cholesterol lowering drugs?
G. Davey Smith (1992)
10.1074/jbc.274.46.32725
Sterol Response Element-binding Protein 1c (SREBP1c) Is Involved in the Polyunsaturated Fatty Acid Suppression of Hepatic S14 Gene Transcription*
M. Mater (1999)
10.1001/jama.1991.03470090059032
Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men.
T. Strandberg (1991)
10.1016/0005-2760(92)90201-6
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
W. Qin (1992)
10.1093/oxfordjournals.eurheartj.a014994
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
B. Jönsson (1996)
10.1001/JAMA.279.20.1615
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
J. R. Downs (1998)
10.1126/science.2988123
The LDL receptor gene: a mosaic of exons shared with different proteins.
T. Südhof (1985)
10.1016/S0008-6363(98)00329-0
Plaque instability--the real challenge for atherosclerosis research in the next decade?
A. Newby (1999)
10.1001/jama.1971.03180230027005
Premature mortality from coronary heart disease. The Framingham study.
T. Gordon (1971)
10.1073/pnas.90.24.11603
SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element.
X. Hua (1993)
10.1001/JAMA.282.24.2340
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
J. Larosa (1999)
Current perspectives on statins. Circulation
M Miettinen (2000)
10.1101/GAD.844900
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ
J. Repa (2000)
HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal Macrophages
FrancoBernini (1995)
10.1161/01.STR.29.8.1562
Incidence and Risk Factors for Stroke in an Occupational Cohort The PROCAM Study
K. Berger (1998)
Lovastatin increases apoprotein A-I levels in subjects with isolated reductions in high density lipoproteins
HN Ginsberg (1991)
10.1016/S0969-2126(98)00067-7
Co-crystal structure of sterol regulatory element binding protein 1a at 2.3 A resolution.
A. Párraga (1998)
Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice.
E. Emeson (1996)
10.1046/j.1365-2249.1996.907600.x
Generalized immune activation in pulmonary tuberculosis: co‐activation with HIV infection
G. Vanham (1996)
10.1161/01.CIR.80.1.198
Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications
J. Willerson (1989)
10.1073/pnas.94.9.4642
T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse.
H. Dansky (1997)
10.1074/JBC.275.17.12497
Transcriptional Regulation of the ATP Citrate-lyase Gene by Sterol Regulatory Element-binding Proteins*
R. Sato (2000)
10.1111/j.1749-6632.1994.tb17337.x
Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study.
B. Brown (1995)
10.1038/sj.onc.1202322
Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
S. Rao (1998)
10.1016/S0021-9150(98)00014-8
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.
J. Crouse (1998)
10.1074/jbc.270.30.18044
Purification of an Interleukin-1 Converting Enzyme-related Cysteine Protease That Cleaves Sterol Regulatory Element-binding Proteins between the Leucine Zipper and Transmembrane Domains (*)
X. Wang (1995)
10.1073/pnas.93.11.5437
Purification and cDNA cloning of a second apoptosis-related cysteine protease that cleaves and activates sterol regulatory element binding proteins.
J. T. Pai (1996)
10.1056/NEJM198610163151602
Platelet activation in unstable coronary disease.
D. Fitzgerald (1986)
10.1172/JCI119746
Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene.
H. Shimano (1997)
10.1074/jbc.271.17.10379
Regulated Cleavage of Sterol Regulatory Element Binding Proteins Requires Sequences on Both Sides of the Endoplasmic Reticulum Membrane (*)
X. Hua (1996)
10.1006/bbrc.1995.2651
Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated.
M. Aviram (1995)
10.1074/jbc.273.10.5785
Cleavage of Sterol Regulatory Element-binding Proteins (SREBPs) at Site-1 Requires Interaction with SREBP Cleavage-activating Protein
J. Sakai (1998)
10.1016/S0021-9150(97)00100-7
Processes in atherogenesis: complement activation.
J. Torzewski (1997)
Effect of lovastatin on cardiovascular resource utilization and costs in the Airforce Coronaryrrexas Coronary Atherosclerosis Prevention Study (AFCAPSrrexCAPs)
AM Gotto (2000)
ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand.
J. Kim (1998)
10.1016/S0140-6736(96)07591-5
Production of C-reactive protein and risk of coronary events in stable and unstable angina
E. Haverkate (1997)
10.1146/ANNUREV.IMMUNOL.16.1.111
CD40 and CD154 in cell-mediated immunity.
I. Grewal (1998)
10.1073/PNAS.98.4.1477
Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands.
R. DeBose-Boyd (2001)
10.1056/nejm199006073222304
Changes in risk factors and the decline in mortality from cardiovascular disease.
R. M. Norris (1990)
10.1074/jbc.272.19.12778
Cleavage Site for Sterol-regulated Protease Localized to a Leu-Ser Bond in the Lumenal Loop of Sterol Regulatory Element-binding Protein-2*
E. A. Duncan (1997)
10.1073/PNAS.94.24.12975
Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins.
J. Swinnen (1997)
Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1).
R. Sato (1994)
10.1172/JCI6246
Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL.
J. Horton (1999)
Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60/ADR cells in vitro: resistance to the mevalonate pathway inhibitor lovastatin.
L. Hunakova (1997)
10.1172/JCI118951
Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.
H. Shimano (1996)
10.1074/jbc.274.19.13025
Co-stimulation of Promoter for Low Density Lipoprotein Receptor Gene by Sterol Regulatory Element-binding Protein and Sp1 Is Specifically Disrupted by the Yin Yang 1 Protein*
M. Bennett (1999)
10.1073/pnas.88.11.4651
Nitric oxide: an endogenous modulator of leukocyte adhesion.
P. Kubes (1991)
10.1161/01.ATV.17.10.1910
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
M. Cuchel (1997)
10.1016/0026-0495(89)90252-7
Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men.
T. Miettinen (1989)
10.1210/EDRV.20.5.0380
Peroxisome proliferator-activated receptors: nuclear control of metabolism.
B. Desvergne (1999)
10.1177/0272989X9301300202
The Beaver Dam Health Outcomes study
D. Fryback (1993)
10.1074/jbc.271.40.24359
Synergistic Binding of Sterol Regulatory Element-binding Protein and NF-Y to the Farnesyl Diphosphate Synthase Promoter Is Critical for Sterol-regulated Expression of the Gene*
J. Ericsson (1996)
10.1016/S0002-9149(01)01451-5
Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
J. Shepherd (2001)
10.1074/JBC.273.5.2738
Secretory Sphingomyelinase, a Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral pH
S. L. Schissel (1998)
10.1016/J.ATHEROSCLEROSISSUP.2004.08.025
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
D. Bilheimer (1983)
10.1006/scel.1994.1047
Protein kinases and cell cycle control.
J. Pines (1994)
10.1016/0021-9150(88)90107-4
Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
G. Vega (1988)
10.1016/S0140-6736(05)79893-7
Increased thrombotic vascular events after change of statin
M. Thomas (1998)
10.1073/PNAS.97.12.6340
Nutrient regulation of gene expression by the sterol regulatory element binding proteins: increased recruitment of gene-specific coregulatory factors and selective hyperacetylation of histone H3 in vivo.
M. Bennett (2000)
10.1097/00041433-199712000-00005
Stabilization of atherosclerotic plaque during lipid lowering.
D. Müller-Wieland (1997)
10.1172/JCI119248
Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells.
H. Shimano (1997)
10.1016/S0140-6736(95)92477-9
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease
I. U. Haq (1995)
10.1074/jbc.272.32.20213
Identification of Complexes between the COOH-terminal Domains of Sterol Regulatory Element-binding Proteins (SREBPs) and SREBP Cleavage-Activating Protein*
J. Sakai (1997)
10.1016/0026-0495(90)90256-C
The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
D. D. Illingworth (1990)
10.1073/pnas.88.18.8154
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization.
A. Henney (1991)
cells. A possible initiating event in atherosclerotic lesion formation
E Trogan (1995)
domain in the regulated degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase
RA DeBose-Boyd (1999)
10.1201/b14304-5
Comparative chemistry, pharmacology and mechanism of action of the statins
A. Gaw (2003)
SREBP cleavage-activating protein causes sterol resistance in three mutant Chinese hamster ovary cell lines
J. Kotzka (1998)
10.1016/0092-8674(94)90234-8
SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis
X. Wang (1994)
10.1001/JAMA.279.20.1643
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
R. Rosenson (1998)
10.1073/pnas.90.14.6434
Lipid advanced glycosylation: pathway for lipid oxidation in vivo.
R. Bucala (1993)
10.1006/phrs.1996.0009
Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
A. Corsini (1996)
10.1161/01.cir.92.11.3172
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.
L. Lacoste (1995)
Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin.
H. Wada (1992)
10.1161/01.ATV.12.7.807
Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.
M. Uusitupa (1992)
10.1016/B978-0-12-024914-5.50008-5
Regulation of HMG-CoA reductase.
V. Rodwell (1976)
10.1073/PNAS.96.1.133
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
J. Fisher (1999)
10.1016/S0002-9149(98)00641-9
Cost-effectiveness of statins.
D. Huse (1998)
10.1161/01.CIR.103.7.926
Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization
M. Crisby (2001)
10.1073/PNAS.040574197
Sterol regulation of human fatty acid synthase promoter I requires nuclear factor-Y- and Sp-1-binding sites.
S. Xiong (2000)
10.1159/000177139
Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
A. Corsini (1996)
10.1056/NEJM199007263230403
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
E. Reihnér (1990)
10.1016/S0005-2760(97)00182-3
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
J. Bergstrom (1998)
10.1101/GAD.891301
SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation.
M. Matsuda (2001)
10.1016/S0002-9149(01)01454-0
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
F. McTaggart (2001)
10.1016/S0021-9150(97)00168-8
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
F. Raal (1997)
10.1007/BF03044602
T-lymphocytes and monocytes in atherogenesis
G. Schmitz (2009)
10.1016/0021-9150(94)05448-R
Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol.
C. Opper (1995)
10.1159/000236952
Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis.
G. Wick (1995)
10.1172/JCI117637
Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.
T. Münzel (1995)
Recognition by Max of its cognate DNA trough a dimeric blHLH/Z
AR Ferre-D' Arnare (1993)
X-ceptors, nuclear receptors for metabolism
J. Auwerx (2000)
10.1161/01.ATV.19.1.54
Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries.
G. Pasterkamp (1999)
10.1016/S0140-6736(81)91338-6
EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE: Report from the Oslo Study Group of a Randomised Trial in Healthy Men
I. Hjermann (1981)
Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis
S McMahon (1998)
Regulation of the rat neutral cytosolic cholesteryl ester hydrolase promoter by hormones and sterols: a role for nuclear factor-Y in the sterol-mediated response.
R. Natarajan (1999)
10.1002/jcp.1041450208
Reversal of lovastatin‐mediated inhibition of natural killer cell cytotoxicity by interleukin 2
J. Cutts (1990)



Semantic Scholar Logo Some data provided by SemanticScholar